BR112021024231A2 - Proteínas de ligação fap recombinantes e uso da mesma - Google Patents

Proteínas de ligação fap recombinantes e uso da mesma

Info

Publication number
BR112021024231A2
BR112021024231A2 BR112021024231A BR112021024231A BR112021024231A2 BR 112021024231 A2 BR112021024231 A2 BR 112021024231A2 BR 112021024231 A BR112021024231 A BR 112021024231A BR 112021024231 A BR112021024231 A BR 112021024231A BR 112021024231 A2 BR112021024231 A2 BR 112021024231A2
Authority
BR
Brazil
Prior art keywords
binding proteins
nucleic acids
fap
recombinant
pharmaceutical compositions
Prior art date
Application number
BR112021024231A
Other languages
English (en)
Inventor
Clara Metz
Dan Snell
Roland Müller Mischa
Ulrike Fiedler
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of BR112021024231A2 publication Critical patent/BR112021024231A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

proteínas de ligação fap recombinantes e uso da mesma. a presente invenção refere-se a proteínas de ligação recombinantes que compreendem um domínio de repetição de anquirina projetado com especificidade de ligação para a proteína de ativação de fibroblastos (fap). além disso, a invenção se refere a ácidos nucleicos que codificam tais proteínas de ligação, composições farmacêuticas que compreendem tais proteínas de ligação ou ácidos nucleicos, e ao uso de tais proteínas de ligação, ácidos nucleicos ou composições farmacêuticas em métodos para localizar ou liberar uma molécula biologicamente ativa em tecido que expressa fap, como tecido tumoral, e para tratar, diagnosticar ou capturar imagens de doenças, como câncer, em um mamífero, incluindo um ser humano.
BR112021024231A 2019-06-04 2020-06-03 Proteínas de ligação fap recombinantes e uso da mesma BR112021024231A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19178277 2019-06-04
PCT/EP2020/065317 WO2020245173A1 (en) 2019-06-04 2020-06-03 Recombinant fap binding proteins and their use

Publications (1)

Publication Number Publication Date
BR112021024231A2 true BR112021024231A2 (pt) 2022-04-26

Family

ID=66857625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024231A BR112021024231A2 (pt) 2019-06-04 2020-06-03 Proteínas de ligação fap recombinantes e uso da mesma

Country Status (12)

Country Link
US (1) US20220242973A1 (pt)
EP (1) EP3980045A1 (pt)
JP (1) JP2022535415A (pt)
KR (1) KR20220016942A (pt)
CN (1) CN114269366A (pt)
AU (1) AU2020286600A1 (pt)
BR (1) BR112021024231A2 (pt)
CA (1) CA3139164A1 (pt)
IL (1) IL288610A (pt)
MX (1) MX2021014601A (pt)
SG (1) SG11202112925PA (pt)
WO (1) WO2020245173A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007122A (es) 2019-12-11 2022-09-09 Molecular Partners Ag Dominios de repetición de anquirina diseñados con residuos de superficie alterados.
CA3176845A1 (en) 2020-05-06 2021-11-11 Patrick AMSTUTZ Novel ankyrin repeat binding proteins and their uses
CA3176497A1 (en) 2020-05-07 2021-11-11 Fatima MECHTA-GRIGORIOU Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2024003393A1 (en) * 2022-06-30 2024-01-04 Navigo Proteins Gmbh Fusion proteins with half life extending domains
WO2024074706A1 (en) 2022-10-07 2024-04-11 Universität Zürich Paracrine adenoviral delivery of biomolecules

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE448301T1 (de) 2000-09-08 2009-11-15 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
WO2009040338A1 (en) 2007-09-24 2009-04-02 University Of Zürich Designed armadillo repeat proteins
ES2758352T3 (es) 2010-11-26 2020-05-05 Molecular Partners Ag Proteínas de repetición diseñadas que se une a la seroalbúmina
AU2012249359A1 (en) * 2011-04-29 2013-11-14 Janssen Biotech, Inc. IL4/IL13 binding repeat proteins and uses
AU2013283296A1 (en) * 2012-06-28 2015-02-05 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP3004152B1 (en) * 2013-05-31 2020-09-30 Molecular Partners AG Designed ankyrin repeat proteins binding to hepatocyte growth factor
KR102236367B1 (ko) * 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
US20150126458A1 (en) * 2013-11-05 2015-05-07 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
BR112017020986A2 (pt) * 2015-04-02 2018-08-14 Molecular Partners Ag. proteínas de ligação recombinantes e seu uso
WO2017210600A1 (en) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
US10717772B2 (en) * 2016-09-22 2020-07-21 Molecular Partners Ag Recombinant binding proteins targeting HER2 and serum albumin, and their uses

Also Published As

Publication number Publication date
WO2020245173A1 (en) 2020-12-10
CA3139164A1 (en) 2020-12-10
JP2022535415A (ja) 2022-08-08
AU2020286600A1 (en) 2021-12-23
KR20220016942A (ko) 2022-02-10
SG11202112925PA (en) 2021-12-30
CN114269366A (zh) 2022-04-01
IL288610A (en) 2022-02-01
US20220242973A1 (en) 2022-08-04
MX2021014601A (es) 2022-02-11
EP3980045A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
BR112021024231A2 (pt) Proteínas de ligação fap recombinantes e uso da mesma
Pietrovito et al. Bone marrow‐derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition
BR112019000598A2 (pt) rna para terapia de câncer
Fan et al. Shikonin reduces TGF-β1-induced collagen production and contraction in hypertrophic scar-derived human skin fibroblasts
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
AR061170A1 (es) Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112022023049A2 (pt) Proteínas multiespecíficas
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
BR112017017825A2 (pt) semaforinas 3 não naturais e seu uso médico
BR112012004546A8 (pt) Terapêutica por proteínas ligantes dll4-ligantes
BR112022011456A2 (pt) Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas
GT201200275A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
BR112021008774A2 (pt) Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica
BR112022012324A2 (pt) Composições e métodos para modular simultaneamente expressão de genes
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112023015831A2 (pt) Ligantes de proteína de ativação de fibroblastos bivalentes para aplicações de liberação direcionada
ECSP15028696A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22
Xu et al. Mitochondrial translocation of Nur77 induced by ROS contributed to cardiomyocyte apoptosis in metabolic syndrome
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
BR112019006174A2 (pt) proteina terapêutica